Trading Halt Update: Novitas Proposes Changes to LCD

29 July 2022

TRADING HALT UPDATE: NOVITAS PROPOSES CHANGES TO LCD

DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) became aware overnight (NZT) of the inclusion of Cxbladder CPT codes in a draft proposal for a different approach to determine which cancer biomarker tests are eligible for reimbursement by Novitas.
The publication of the proposed approach for Genetic Testing in Oncology is set out in a draft Local Coverage Determination (LCD, DL39365) and a draft Local Coverage Article (LCA, DA59125).
Pacific Edge will provide its shareholders with further clarification of the implications for Pacific Edge once it has received advice from its US legal team and other advisors prior to lifting the current trading halt.


Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.  

For more information:

Dr Peter Meintjes
Chief Executive
Pacific Edge
P: +64 22 032 1263

---

Announcement PDF